Persistence of glutamic acid decarboxylase antibody (GADA) is associated with clinical characteristics of latent autoimmune diabetes in adults: a prospective study with 3-year follow-up

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 6, 2016, Pages 615-622

  Huang, Gan ^a   Yin, Min ^a   Xiang, Yufei ^a   Li, Xia ^a   Shen, Wei ^a   Luo, Shuoming ^a   Lin, Jian ^a   Xie, Zhiguo ^a   Zheng, Peilin ^a   Zhou, Zhiguang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

glutamic acid decarboxylase antibody; latent autoimmune diabetes in adults; type 2 diabetes mellitus; cell function

Indexed keywords

AUTOANTIBODY; C PEPTIDE; EPITOPE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; HLA DQ ANTIGEN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENOTYPE; HAPLOTYPE; HUMAN; LATENT AUTOIMMUNE DIABETES IN ADULTS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION;

EID: 84985986849     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2779     Document Type: Article

References (23)

1. Hawa MI, Buchan AP, Ola T, et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Diabetes Care 2014; 37: 1643–1649.
2. Guglielmi C, Palermo A, Pozzilli P. Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy. Diabetes Metab Res Rev 2012; 28(Suppl 2): 40–46.
3. Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 2013; 62: 543–550.
4. Fourlanos S, Dotta F, Greenbaum CJ, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005; 48: 2206–2212.
5. Itariu BK, Stulnig TM. Autoimmune aspects of type 2 diabetes mellitus – a mini-review. Gerontology 2014; 60: 189–196.
6. Xiang YF, Zhao YJ, Zhou ZG. Latent autoimmune diabetes in adults: evidences for diabetes spectrum? Chin Med J 2013; 126: 783–788.
7. Zampetti S, Capizzi M, Spoletini M, et al. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). J Clin Endocrinol Metab 2012; 97: 3759–3765.
8. Mahadeb YP, Gruson D, Buysschaert M, et al. What are the characteristics of phenotypic type 2 diabetic patients with low-titer GAD65 antibodies? Acta Diabetol 2014; 51: 103–111.
9. Zampetti S, Campagna G, Tiberti C, et al. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7). Eur J Endocrinol 2014; 171: 697–704.
10. Li X, Zhou ZG, Huang G, et al. Optimal cutoff point of glutamate decarboxylase antibody titers in differentiating two subtypes of adult-onset latent autoimmune diabetes. Ann N Y Acad Sci 2004; 1037: 122–126.
11. Jin P, Huang G, Lin J, et al. Epitope analysis of GAD65 autoantibodies in adult-onset type 1 diabetes and latent autoimmune diabetes in adults with thyroid autoimmunity. Acta Diabetol 2011; 48: 149–155.
12. Barker JM, Barriga KJ, Yu L, et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004; 89: 3896–3902.
13. Sorgjerd EP, Skorpen F, Kvaloy K, et al. Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study, Norway. Diabetologia 2012; 55: 1310–1318.
14. World Health Organization, Department of Noncommunicable Disease Surveillance. Definition, Diagnosis and Classification of Diabetes and Its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes. World Health Org: Geneva, Switzerland, 1999; 1–59.
15. Petersen JS, Hejnaes KR, Moody A, et al. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 1994; 43: 459–467.
16. Huang G, Xiang Y, Pan L, et al. Zinc transporter 8 autoantibody (ZnT8A) could help differentiate latent autoimmune diabetes in adults (LADA) from phenotypic type 2 diabetes mellitus. Diabetes Metab Res Rev 2013; 29: 363–368.
17. Triolo TM, Baschal EE, Armstrong TK, et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. J Clin Endocrinol Metab 2009; 94: 4517–4523.
18. Lin J, Zhou ZG, Wang JP, et al. From type 1, through LADA, to type 2 diabetes: a continuous spectrum? The evidence of the HLA-DQ gene. Ann NY Acad Sci 2008; 1150: 99–102.
19. Liu L, Li X, Xiang Y, et al. Latent autoimmune diabetes in adults with low-titer GAD antibodies: similar disease progression with type 2 diabetes: a nationwide, multicenter prospective study (LADA China study 3). Diabetes Care 2015; 38: 16–21.
20. Chao C, Huang G, Li X, et al. Change of glutamic acid decarboxylase antibody and protein tyrosine phosphatase antibody in Chinese patients with acute-onset type 1 diabetes mellitus. Chin Med J (Engl) 2013; 126: 4006–4012.
21. Borg H, Gottsater A, Fernlund P, et al. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002; 51: 1754–1762.
22. Hawa MI, Kolb H, Schloot N, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013; 36: 908–913.
23. Ronkainen MS, Savola K, Knip M. Antibodies to GAD65 epitopes at diagnosis and over the first 10 years of clinical type 1 diabetes mellitus. Scand J Immunol 2004; 59: 334–340.